AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...
EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...
GlobalData on MSN12d
EU set to approve AstraZeneca’s Imfinzi-chemo combo for NSCLCAstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...
AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the pivotal AEGEAN trial, which were published in The ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the pivotal AEGEAN trial, which were published in The ...
AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for ...
Imfinzi in combination with chemotherapy has been recommended for approval in the European Union for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback